SlideShare a Scribd company logo
1 of 67
Download to read offline
BY DR KUMAR GOURAV
PG resident, pharmacology
1
 Definition
 Introduction
 Regulatory framework of India
 Rules in schedule Y
 Good clinical practice rules
 Informed consent
 Amendments
 Organisation
 Institutional ethical committee
 Compensation rules
 SAE reporting
2
 Schedule Y refers to the requirements and
guidelines for permission:
1. To import
2. Manufacture of new drugs for sale or
3. To undertake clinical trials in India.
3
 At present the following acts and rules regulate the
manufacture, export and clinical research of drugs
and cosmetics in India :
1. Drugs and Cosmetics Act, 1940
2. Drugs and Cosmetics rules, 1945
3. Pharmacy Act, 1948
4. Drugs and Magic Remedies (Objectionable
Advertisements) Act, 1954
4
5. Narcotic Drugs and Psychotropic Substances
Act,1985
6. Medicinal and Toilet preparation (Excise Duties)
Act, 1955
7. Drugs (Price Control ) Order, 1955 under Essential
Commodities Act, 1955
5
 The Main regulatory laws operating in India are
the Drug and Cosmetics Act (1940) and the Drugs
and Cosmetics Rules (1945).
 The Act and Rules are binding on allopathic and
other systems of medicine and regulate imports,
manufacture, distribution, and sale of drugs in
India
6
 The enforcement came into existence in 1988 .
 Revised version of Schedule Y in line with ICH-
GCP (International Council of Harmonization and
Good Clinical Practice) standard was put forth in
1995.
7
 Rules 122 A, 122 B, 122 D, 122 DA, 122 DAA,
122 DAB, 122 E, 122 DD of the Drugs and
Cosmetics Rules (1945) deals with schedule Y
8
RULES PERMISSION FOR
122 A To import New drugs
122 B To manufacture New drugs
122 D To Import or Manufacture fixed dose combinations
122 DA To conduct clinical trials for New Drug/Investigational
New drug
122 DAA Definition of Clinical Trial
122 DAB Reports of Serious Adverse Events (SAEs) including
deaths.
122 E New Drug
122 DD Registration of Ethics Committee (EC).
9
 A systematic study of new drug(s) in human
subject(s) to generate data for discovering and/or
verifying the clinical, pharmacological (including
pharmaco –dynamic and pharmaco -kinetic) and/or
adverse effects with the objective of determining
safety and/ or efficacy of the new drug.
10
 A drug which has not been used in the country ,
new claim for a drug already approved, FDC
(combined for the first time or change in ratio) and
all vaccines.
11
 Some highlights of Schedule Y in terms of its appendices;
which provide the guidelines to conduct clinical trials are:
 Appendix V – Informed consent
Appendix VII – Undertaking by the
Investigator
Appendix VIII – Ethics Committee
Appendix X – Contents of Protocol
Appendix XI – Data elements for reporting
SAE
12
 It shall made in Form 44 accompanied with the
following data in accordance with appendices,
namely
1. Clinical and pharmaceutical information
2. Animal pharmacology data
3. Animal Toxicology data
4. Human Clinical pharmacology data
5. Regulatory status in other countries
6. Prescribing information
13
1. Approval for Clinical trials
 Clinical trials on a New drug shall be initiated only after
permission by licensing authority and approval from EC .
 All trial Investigator(s) should possess appropriate
qualifications,
 Protocol amendments if become necessary before initiation
or during the course of a clinical trial, all such amendments
should be notified to the Licensing Authority in writing
14
2. Responsibilities of Sponsor
 Implementing and maintaining quality assurance
 Submit status report to the licensing authority periodically
 Serious adverse event (SAE) should be reported to the
licensing authority within 14 calendar days.
 In case of studies prematurely discontinued for any reason
including lack of commercial interest in pursuing the new
drug application, a summary report should be submitted
within 3 months.
15
3. Responsibilities of Investigator
 The Investigator(s) shall be responsible for the conduct
of the trial according to the protocol
 Ensure adequate medical care is provided to the
subject
 SAE and unexpected AE should be reported to the
sponsor within 24 hrs and to the EC within 7 working
days
16
4.Informed consent
 Freely given informed written consent
 Provide information about the study verbally and
in written
 Non-Technically and understandable
language.
 Legally acceptable representative
17
5.Responsibilities of ethics committee
 Approval trial protocol to safe guard right, safety
and well being of all trial subject
 Particular care to protect right, safety and well
being of all vulnerable subjects
18
1. Geriatrics
They should be included in Phase III clinical trials (and
in Phase II trials, at the Sponsor's option) in meaningful
numbers, if
1. The disease is characteristically a disease of aging
2. Substantial numbers of geriatric patients
25
3.Common in the elderly are likely to be encountered
4.When the new drug is likely to alter the geriatric
patient's response
26
 Begin with older children before extending the
trial to younger children and then infants.
 If the new drug is for diseases predominantly or
exclusively affecting paediatric patients, clinical
trial data should be generated in the paediatric
population except for initial safety and tolerability
data
27
 Diseases occurring in both adults and pediatric
patients, for which there are currently no or limited
therapeutic options, pediatric population should be
included in the clinical trials early, following
assessment of initial safety data and reasonable
evidence of potential benefit.
 Written informed consent should be obtained from
the parent/legal guardian.
28
 They should be included in clinical trials only
when the drug is intended for use by
pregnant/nursing women or fetus / nursing infants
 Where the data generated from women who are
not pregnant or nursing, is not suitable.
29
 follow-up data on the pregnancy, fetus and child
will be required.
 Where applicable, excretion of the drug or its
metabolites into human milk should be examined
30
 closely monitored new drugs clinical safety
 Periodic Safety Update Reports (PSUR)-
to report all relevant new information
 PSUR shall be submitted every 6months for the
first 2 years
 New studies specifically planned or conducted to
examine a safety issue should be described in the
PSURs.
31
 conducted according to the guidance for BA and
BE studies
 Evaluation of the effect of food on absorption
following oral administration
 All bioavailability and bioequivalence studies
should be conducted according to the Guidelines
for Bioavailability and Bioequivalence studies as
prescribed.
32
 Good Clinical Practices (GCP) is an international
ethical & scientific quality standard for designing,
conducting, recording & reporting trials that
involve the participation of human subjects.
 It ensures the : RIGHTS
SAFETY
WELL BEING
33
 The International Conference on Harmonization of
Technical Requirements for Registration of
Pharmaceuticals for Human Use (ICH) is a joint
initiative of the experts in pharmaceutical industry
of Europe, Japan and the United States to discuss
scientific and technical aspects of pharmaceutical
product registration.
34
 Released in Dec 2001(Developed by CDCSO and
endorsed by DCGI)
 In general, in line with ICH GCP
 Has Revised Schedule Y (Jan 2005)
35
 2.1 Clinical trials should be conducted in
accordance with the ethical principles that have
their origin in the Declaration of Helsinki, and that
are consistent with GCP and the applicable
regulatory requirement(s).
36
 2.2 Before a trial is initiated, risks and
inconveniences should be weighed against the
anticipated benefit for the individual , trial subject
and society. A trial should be initiated and
continued only if the anticipated benefits justify
the risks.
37
 2.3 The rights, safety, and well-being of the trial
subjects are the most important considerations and
should prevail over interests of science and society.
 2.4 The available nonclinical and clinical
information on an investigational product should
be adequate to support the proposed clinical trial.
38
 2.5 Clinical trials should be scientifically sound,
and described in a clear, detailed protocol.
 2.6 A trial should be conducted in compliance with
the protocol that has received prior institutional
review board (IRB)/independent ethics committee
(IEC) approval/favorable opinion.
39
 2.7 The medical care given to, and medical
decisions made on behalf of, subjects should
always be the responsibility of a qualified
physician or, when appropriate, of a qualified
dentist.
 2.8 Each individual involved in conducting a trial
should be qualified by education, training, and
experience to perform his or her respective task(s).
40
 2.9 Freely given informed consent should be
obtained from every subject prior to clinical trial
participation.
 2.10 All clinical trial information should be
recorded, handled, and stored in a way that allows
its accurate reporting, interpretation and
verification.
41
 2.11 The confidentiality of records that could identify
subjects should be protected, respecting the privacy.
 2.12 Investigational products should be manufactured,
handled, and stored in accordance with applicable good
manufacturing practice (GMP).
 2.13 Systems with procedures that assure the quality of
every aspect of the trial should be implemented.
42
1. Participation
2. Title
3. Research team
4. Research funding
5. Study location
6. A brief introduction about the study
7. Need for the study
43
8. No of participants
9. Reason for inclusion of that participant.
10. Duration of participation
11. Methodology in detail
12. Responsibility of the participant.
13. Benefit of the study
14. Risk of the study
44
15. Protection from harm
16. Privacy
17. Protection of privacy
18. Confidentiality
19. Compensation
20. Use of data
21. Voluntariness, no force
45
22. Right to refuse, right to withdraw, patient
care right not affected
23. Time to decide
24. Clarify doubts: contact information
25. Retain a copy
46
 Same thing should be written by the
participant with : Name
Date
Address
Phone no
47
48
 Rule 122DAB –Compensation in case of injury or
death during clinical trial(CT).
 Rule 122DAC- Permission to conduct Clinical
Trial subject to certain Conditions, Authority for
CT inspections, Actions in case of non-compliance
 Rule 122DD -Registration of Ethics Committee -
Requirements and guidelines for registration of
Ethics Committee
49
 Informed Consent
1. A-V recording of informed consent process is
required for vulnerable subjects in NCE/ NME trials.
2. For anti-HIV & anti-leprosy drug trials, only audio
recording.
3. Essential elements in ICF
–Possibility of failure of investigational
product .
–Placebo will not any therapeutic effect .
50
 The CT in relation to a new drug or investigational
new drug in humans has to generate data for
discovering or verifying its pharmacological
interactions including pharmacodynamics,
pharmacokinetic and adverse effects in order to
determine the safety, efficacy or tolerance of new
drugs.
51
 The New Drug Regulatory Process come under the
purview of the Drugs Controller General of India
(DCGI), who is the head of the Central Drugs
Standard Control Organization (CDSCO), located
in New Delhi.
52
53
 The DCGI is supported by various bodies, such as
the Indian Council of Medical Research (ICMR)
and Department of Biotechnology (DBT) in the
evaluation of specific therapies or clinical trials.
 The ICMR, for example, provides expert advice in
evaluation of Phase I trials or clinical trials
relevant to national priorities, eg, malaria, AIDS
etc.
54
Consist of 8-12 members:
1. Chairperson
2. 1-2 from basic medical science area
3. 1-2 clinicians
4. 1 legal expert
5. 1 representative of NGO
6. 1 philosopher
7. 1 lay person from the society
8. Member secretary
55
 To provide competent review of all ethical aspects
of the project
 Undertake review free from bias and influence
 Provide advice to the researchers on all aspects of
welfare and safety of research participants
 To protect dignity, rights and well-being of the
potential research participants.
56
 To ensure universal ethical values and international
scientific standards in terms of local community
values and customs.
 To assist in the development and the education of
research community responsive to local health care
requirements
57
58
 Rule of compensation applies to only those adverse
events (AEs) that are required to be reported.
 As per the rules, all serious AEs (SAEs) are to be
reported within a stipulated time frame.
 AE that do not fall into the SAE category are not
required to be expeditiously reported and, therefore, do
not fall under the clause of compensation.
59
 The final formula for calculating compensation is:
(8,00,000 x age factor x risk factor)
99.37
-where 800,000 rupees is the base amount;
-age factor varies from 228.54 (≤ 16 years) to 99.37
(≥ 65 years);
-the risk factor (ranging from 0.5 to 4.0) is decided
on the basis of trial participants
60
(i) SAE causing permanent disability to the subject.
Compensation = (D x 80 x C)
100 x 100
where, D = percentage disability the subject has
suffered,
C = quantum of compensation which would have
been due for payment to the subject’s nominee(s)
in case of death of the subject
61
(ii) SAE causing congenital anomaly or birth defect.
The following four situations may arise due to congenital
anomaly or birth defect:
(a) Still birth.
(b) Early death due to anomaly.
(c) No death but deformity which can be fully corrected
through appropriate intervention.
(d) Permanent disability (mental or physical)
62
 For all the above-mentioned situations,
compensation of a fixed amount of 400,000 rupees
is applicable.
 However, for situations (c) and (d), medical
management, as long as required, has to be
provided by the sponsor, in addition to the above-
mentioned fixed amount of 400,000 rupees.
63
(iii) SAE causing life-threatening disease.
Compensation = N x W
where N = number of days for which the trial subject
remained in a life-threatening situation requiring
medical care, irrespective of number of days of
hospitalization;
W = minimum wage per day of an unskilled worker.
64
(iv) Reversible SAE in case it is resolved.
In this situation, the compensation amount will be
double the amount applicable for situation (iii),
explained above.
65
66
 An event is serious when the patient outcome is:
1. death
2. Is life-threatening
3. Requires inpatient hospitalization or prolongation of
existing hospitalization
4. Results in persistent or significant
Disability/incapacity
5. Is a congenital anomaly/birth defect
6. Require intervention to prevent permanent damage
67
A. As per the regulations (Schedule Y of Drugs &
Cosmetics Rules), all Unexpected SAEs have to
be reported to CDSCO within 14 calendar days.
B. Every report (both initial as well as follow-up
reports) should be submitted along with a
covering letter. A template of covering letter is
available in Annexure II.
68
C. Covering letter should be prepared using the
template as guide, and printed on the company’s/
CRO’s letter head.
D. Instructions are provided in the template as
highlighted text in “Italics”. Please delete all
instructions from your final letter.
69
E. All the sections of the covering letter should be
completed.
G. Capture whether it is “initial” or “follow-up”
report.
70
71
 http://www.cdsco.nic.in/writereaddata/CDSCO-
GuidanceForIndustry.pdf
 Drugs and Cosmetics act and rules 1945 available at
http://www.cdsco.nic.in/writereaddata/Drugs&CosmeticAct. pdf
 Gupta YK, Pradhan AK, Goyal A, Mohan P. Compensation for
clinical trial-related injury and death in India: Challenges and
the way forward. Drug Saf. 2014;37:995–1002.
72
73

More Related Content

What's hot

Investigational New drug application [INDA]
Investigational New drug application [INDA]Investigational New drug application [INDA]
Investigational New drug application [INDA]Sagar Savale
 
Safety monitoring in clinical trails
Safety monitoring in clinical trailsSafety monitoring in clinical trails
Safety monitoring in clinical trailsGOURIPRIYA L S
 
WHO International Drug Monitoring Program
WHO International Drug Monitoring ProgramWHO International Drug Monitoring Program
WHO International Drug Monitoring ProgramSnehaKhandale1
 
institutional review board and independent ethics committee
institutional review board and independent ethics committeeinstitutional review board and independent ethics committee
institutional review board and independent ethics committeeMOHAMMAD ASIM
 
ICH safety guidelines
ICH safety guidelinesICH safety guidelines
ICH safety guidelinesvishnu Jatoth
 
INSTITUTIONAL REVIEW BOARD (IRB/IEC).pptx
INSTITUTIONAL REVIEW BOARD (IRB/IEC).pptxINSTITUTIONAL REVIEW BOARD (IRB/IEC).pptx
INSTITUTIONAL REVIEW BOARD (IRB/IEC).pptxRAHUL PAL
 
Institutional review board by akshdeep sharma
Institutional review board by akshdeep sharmaInstitutional review board by akshdeep sharma
Institutional review board by akshdeep sharmaAkshdeep Sharma
 
Assignment on Regulatory Prespectives of Clinical Trials
Assignment on Regulatory Prespectives of Clinical TrialsAssignment on Regulatory Prespectives of Clinical Trials
Assignment on Regulatory Prespectives of Clinical TrialsDeepak Kumar
 
regulatory perspectives of clinical trails
regulatory perspectives of clinical trails regulatory perspectives of clinical trails
regulatory perspectives of clinical trails Pankaj Maurya
 
INVESTIGATOR’S BROCHURE (IB)
 INVESTIGATOR’S BROCHURE (IB) INVESTIGATOR’S BROCHURE (IB)
INVESTIGATOR’S BROCHURE (IB)SachinFartade
 
Establishing Pharmacovigilance Centres In Hospital.pptx
Establishing Pharmacovigilance Centres In Hospital.pptxEstablishing Pharmacovigilance Centres In Hospital.pptx
Establishing Pharmacovigilance Centres In Hospital.pptxRushikeshTidake
 
Good Clinical Practice and Pharmacovigilance
Good Clinical Practice and PharmacovigilanceGood Clinical Practice and Pharmacovigilance
Good Clinical Practice and PharmacovigilanceMd. Zakaria Faruki
 
Roles and responsibilities in clinical trials
Roles and responsibilities in clinical trialsRoles and responsibilities in clinical trials
Roles and responsibilities in clinical trialsDRx Tejas Kanhed
 
IND (Investigational New Drug) industrial perspective
IND (Investigational New Drug) industrial perspectiveIND (Investigational New Drug) industrial perspective
IND (Investigational New Drug) industrial perspectiveAYESHA NAZEER
 
Investigational New Drug Application
Investigational New Drug ApplicationInvestigational New Drug Application
Investigational New Drug ApplicationSuhas Reddy C
 
Investigator's Brochure
Investigator's BrochureInvestigator's Brochure
Investigator's BrochureRiyaz Gohil
 
clinical trials types and design
clinical trials types and designclinical trials types and design
clinical trials types and designUttara Joshi
 

What's hot (20)

Investigational New drug application [INDA]
Investigational New drug application [INDA]Investigational New drug application [INDA]
Investigational New drug application [INDA]
 
Safety monitoring in clinical trails
Safety monitoring in clinical trailsSafety monitoring in clinical trails
Safety monitoring in clinical trails
 
WHO International Drug Monitoring Program
WHO International Drug Monitoring ProgramWHO International Drug Monitoring Program
WHO International Drug Monitoring Program
 
institutional review board and independent ethics committee
institutional review board and independent ethics committeeinstitutional review board and independent ethics committee
institutional review board and independent ethics committee
 
ICH safety guidelines
ICH safety guidelinesICH safety guidelines
ICH safety guidelines
 
INSTITUTIONAL REVIEW BOARD (IRB/IEC).pptx
INSTITUTIONAL REVIEW BOARD (IRB/IEC).pptxINSTITUTIONAL REVIEW BOARD (IRB/IEC).pptx
INSTITUTIONAL REVIEW BOARD (IRB/IEC).pptx
 
Institutional review board by akshdeep sharma
Institutional review board by akshdeep sharmaInstitutional review board by akshdeep sharma
Institutional review board by akshdeep sharma
 
ICH GCP
ICH GCPICH GCP
ICH GCP
 
Assignment on Regulatory Prespectives of Clinical Trials
Assignment on Regulatory Prespectives of Clinical TrialsAssignment on Regulatory Prespectives of Clinical Trials
Assignment on Regulatory Prespectives of Clinical Trials
 
SEVERITY AND SERIOUSNESS ASSESSMENT OF ADR’S
SEVERITY AND SERIOUSNESS ASSESSMENT OF ADR’SSEVERITY AND SERIOUSNESS ASSESSMENT OF ADR’S
SEVERITY AND SERIOUSNESS ASSESSMENT OF ADR’S
 
regulatory perspectives of clinical trails
regulatory perspectives of clinical trails regulatory perspectives of clinical trails
regulatory perspectives of clinical trails
 
INVESTIGATOR’S BROCHURE (IB)
 INVESTIGATOR’S BROCHURE (IB) INVESTIGATOR’S BROCHURE (IB)
INVESTIGATOR’S BROCHURE (IB)
 
Establishing Pharmacovigilance Centres In Hospital.pptx
Establishing Pharmacovigilance Centres In Hospital.pptxEstablishing Pharmacovigilance Centres In Hospital.pptx
Establishing Pharmacovigilance Centres In Hospital.pptx
 
Good Clinical Practice and Pharmacovigilance
Good Clinical Practice and PharmacovigilanceGood Clinical Practice and Pharmacovigilance
Good Clinical Practice and Pharmacovigilance
 
INVESTIGATIONAL NEW DRUG (IND)
INVESTIGATIONAL NEW DRUG (IND) INVESTIGATIONAL NEW DRUG (IND)
INVESTIGATIONAL NEW DRUG (IND)
 
Roles and responsibilities in clinical trials
Roles and responsibilities in clinical trialsRoles and responsibilities in clinical trials
Roles and responsibilities in clinical trials
 
IND (Investigational New Drug) industrial perspective
IND (Investigational New Drug) industrial perspectiveIND (Investigational New Drug) industrial perspective
IND (Investigational New Drug) industrial perspective
 
Investigational New Drug Application
Investigational New Drug ApplicationInvestigational New Drug Application
Investigational New Drug Application
 
Investigator's Brochure
Investigator's BrochureInvestigator's Brochure
Investigator's Brochure
 
clinical trials types and design
clinical trials types and designclinical trials types and design
clinical trials types and design
 

Similar to Schedule y (20)

GCP and EC Training (2).ppt
GCP and EC Training (2).pptGCP and EC Training (2).ppt
GCP and EC Training (2).ppt
 
Schedule y jjjjjjjjjjjjjjjjjjjppt
Schedule y jjjjjjjjjjjjjjjjjjjpptSchedule y jjjjjjjjjjjjjjjjjjjppt
Schedule y jjjjjjjjjjjjjjjjjjjppt
 
Schedule Y by akshdeep sharma
Schedule Y by akshdeep sharmaSchedule Y by akshdeep sharma
Schedule Y by akshdeep sharma
 
Schedule y
Schedule ySchedule y
Schedule y
 
Seminar schedule 'y'
Seminar schedule   'y'Seminar schedule   'y'
Seminar schedule 'y'
 
Clic
ClicClic
Clic
 
Schedule y
Schedule ySchedule y
Schedule y
 
Dcgi adverse event
Dcgi adverse eventDcgi adverse event
Dcgi adverse event
 
Schedule y -_priti_gupta
Schedule y -_priti_guptaSchedule y -_priti_gupta
Schedule y -_priti_gupta
 
Presentation on Clinical Trial
Presentation on Clinical TrialPresentation on Clinical Trial
Presentation on Clinical Trial
 
Schedule y draft 2
Schedule y draft 2Schedule y draft 2
Schedule y draft 2
 
ICH GCP
ICH GCPICH GCP
ICH GCP
 
Scedule y
Scedule yScedule y
Scedule y
 
GCP ppdf
GCP ppdfGCP ppdf
GCP ppdf
 
Schedule Y Summary
Schedule Y SummarySchedule Y Summary
Schedule Y Summary
 
Summary Of Schedule Y
Summary Of Schedule YSummary Of Schedule Y
Summary Of Schedule Y
 
CLINICAL INVESTIGATION AND EVALUATION OF MEDICAL DEVICES AND.pptx
CLINICAL INVESTIGATION AND EVALUATION OF MEDICAL DEVICES AND.pptxCLINICAL INVESTIGATION AND EVALUATION OF MEDICAL DEVICES AND.pptx
CLINICAL INVESTIGATION AND EVALUATION OF MEDICAL DEVICES AND.pptx
 
INVESTIGATIONAL NEW DRUG APPLICATION
INVESTIGATIONAL NEW DRUG APPLICATIONINVESTIGATIONAL NEW DRUG APPLICATION
INVESTIGATIONAL NEW DRUG APPLICATION
 
INDA/NDA/ANDA
INDA/NDA/ANDAINDA/NDA/ANDA
INDA/NDA/ANDA
 
Schedule Y-2019
Schedule Y-2019Schedule Y-2019
Schedule Y-2019
 

Recently uploaded

AUDIENCE THEORY -- FANDOM -- JENKINS.pptx
AUDIENCE THEORY -- FANDOM -- JENKINS.pptxAUDIENCE THEORY -- FANDOM -- JENKINS.pptx
AUDIENCE THEORY -- FANDOM -- JENKINS.pptxiammrhaywood
 
Presentation on the Basics of Writing. Writing a Paragraph
Presentation on the Basics of Writing. Writing a ParagraphPresentation on the Basics of Writing. Writing a Paragraph
Presentation on the Basics of Writing. Writing a ParagraphNetziValdelomar1
 
HED Office Sohayok Exam Question Solution 2023.pdf
HED Office Sohayok Exam Question Solution 2023.pdfHED Office Sohayok Exam Question Solution 2023.pdf
HED Office Sohayok Exam Question Solution 2023.pdfMohonDas
 
How to Show Error_Warning Messages in Odoo 17
How to Show Error_Warning Messages in Odoo 17How to Show Error_Warning Messages in Odoo 17
How to Show Error_Warning Messages in Odoo 17Celine George
 
How to Add a New Field in Existing Kanban View in Odoo 17
How to Add a New Field in Existing Kanban View in Odoo 17How to Add a New Field in Existing Kanban View in Odoo 17
How to Add a New Field in Existing Kanban View in Odoo 17Celine George
 
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRA
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRADUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRA
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRATanmoy Mishra
 
Patient Counselling. Definition of patient counseling; steps involved in pati...
Patient Counselling. Definition of patient counseling; steps involved in pati...Patient Counselling. Definition of patient counseling; steps involved in pati...
Patient Counselling. Definition of patient counseling; steps involved in pati...raviapr7
 
PISA-VET launch_El Iza Mohamedou_19 March 2024.pptx
PISA-VET launch_El Iza Mohamedou_19 March 2024.pptxPISA-VET launch_El Iza Mohamedou_19 March 2024.pptx
PISA-VET launch_El Iza Mohamedou_19 March 2024.pptxEduSkills OECD
 
How to Use api.constrains ( ) in Odoo 17
How to Use api.constrains ( ) in Odoo 17How to Use api.constrains ( ) in Odoo 17
How to Use api.constrains ( ) in Odoo 17Celine George
 
How to Manage Cross-Selling in Odoo 17 Sales
How to Manage Cross-Selling in Odoo 17 SalesHow to Manage Cross-Selling in Odoo 17 Sales
How to Manage Cross-Selling in Odoo 17 SalesCeline George
 
Human-AI Co-Creation of Worked Examples for Programming Classes
Human-AI Co-Creation of Worked Examples for Programming ClassesHuman-AI Co-Creation of Worked Examples for Programming Classes
Human-AI Co-Creation of Worked Examples for Programming ClassesMohammad Hassany
 
In - Vivo and In - Vitro Correlation.pptx
In - Vivo and In - Vitro Correlation.pptxIn - Vivo and In - Vitro Correlation.pptx
In - Vivo and In - Vitro Correlation.pptxAditiChauhan701637
 
How to Make a Field read-only in Odoo 17
How to Make a Field read-only in Odoo 17How to Make a Field read-only in Odoo 17
How to Make a Field read-only in Odoo 17Celine George
 
Ultra structure and life cycle of Plasmodium.pptx
Ultra structure and life cycle of Plasmodium.pptxUltra structure and life cycle of Plasmodium.pptx
Ultra structure and life cycle of Plasmodium.pptxDr. Asif Anas
 
CapTechU Doctoral Presentation -March 2024 slides.pptx
CapTechU Doctoral Presentation -March 2024 slides.pptxCapTechU Doctoral Presentation -March 2024 slides.pptx
CapTechU Doctoral Presentation -March 2024 slides.pptxCapitolTechU
 
Philosophy of Education and Educational Philosophy
Philosophy of Education  and Educational PhilosophyPhilosophy of Education  and Educational Philosophy
Philosophy of Education and Educational PhilosophyShuvankar Madhu
 
How to Add a many2many Relational Field in Odoo 17
How to Add a many2many Relational Field in Odoo 17How to Add a many2many Relational Field in Odoo 17
How to Add a many2many Relational Field in Odoo 17Celine George
 
Easter in the USA presentation by Chloe.
Easter in the USA presentation by Chloe.Easter in the USA presentation by Chloe.
Easter in the USA presentation by Chloe.EnglishCEIPdeSigeiro
 
Clinical Pharmacy Introduction to Clinical Pharmacy, Concept of clinical pptx
Clinical Pharmacy  Introduction to Clinical Pharmacy, Concept of clinical pptxClinical Pharmacy  Introduction to Clinical Pharmacy, Concept of clinical pptx
Clinical Pharmacy Introduction to Clinical Pharmacy, Concept of clinical pptxraviapr7
 

Recently uploaded (20)

AUDIENCE THEORY -- FANDOM -- JENKINS.pptx
AUDIENCE THEORY -- FANDOM -- JENKINS.pptxAUDIENCE THEORY -- FANDOM -- JENKINS.pptx
AUDIENCE THEORY -- FANDOM -- JENKINS.pptx
 
Presentation on the Basics of Writing. Writing a Paragraph
Presentation on the Basics of Writing. Writing a ParagraphPresentation on the Basics of Writing. Writing a Paragraph
Presentation on the Basics of Writing. Writing a Paragraph
 
HED Office Sohayok Exam Question Solution 2023.pdf
HED Office Sohayok Exam Question Solution 2023.pdfHED Office Sohayok Exam Question Solution 2023.pdf
HED Office Sohayok Exam Question Solution 2023.pdf
 
How to Show Error_Warning Messages in Odoo 17
How to Show Error_Warning Messages in Odoo 17How to Show Error_Warning Messages in Odoo 17
How to Show Error_Warning Messages in Odoo 17
 
How to Add a New Field in Existing Kanban View in Odoo 17
How to Add a New Field in Existing Kanban View in Odoo 17How to Add a New Field in Existing Kanban View in Odoo 17
How to Add a New Field in Existing Kanban View in Odoo 17
 
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRA
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRADUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRA
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRA
 
Patient Counselling. Definition of patient counseling; steps involved in pati...
Patient Counselling. Definition of patient counseling; steps involved in pati...Patient Counselling. Definition of patient counseling; steps involved in pati...
Patient Counselling. Definition of patient counseling; steps involved in pati...
 
PISA-VET launch_El Iza Mohamedou_19 March 2024.pptx
PISA-VET launch_El Iza Mohamedou_19 March 2024.pptxPISA-VET launch_El Iza Mohamedou_19 March 2024.pptx
PISA-VET launch_El Iza Mohamedou_19 March 2024.pptx
 
How to Use api.constrains ( ) in Odoo 17
How to Use api.constrains ( ) in Odoo 17How to Use api.constrains ( ) in Odoo 17
How to Use api.constrains ( ) in Odoo 17
 
Finals of Kant get Marx 2.0 : a general politics quiz
Finals of Kant get Marx 2.0 : a general politics quizFinals of Kant get Marx 2.0 : a general politics quiz
Finals of Kant get Marx 2.0 : a general politics quiz
 
How to Manage Cross-Selling in Odoo 17 Sales
How to Manage Cross-Selling in Odoo 17 SalesHow to Manage Cross-Selling in Odoo 17 Sales
How to Manage Cross-Selling in Odoo 17 Sales
 
Human-AI Co-Creation of Worked Examples for Programming Classes
Human-AI Co-Creation of Worked Examples for Programming ClassesHuman-AI Co-Creation of Worked Examples for Programming Classes
Human-AI Co-Creation of Worked Examples for Programming Classes
 
In - Vivo and In - Vitro Correlation.pptx
In - Vivo and In - Vitro Correlation.pptxIn - Vivo and In - Vitro Correlation.pptx
In - Vivo and In - Vitro Correlation.pptx
 
How to Make a Field read-only in Odoo 17
How to Make a Field read-only in Odoo 17How to Make a Field read-only in Odoo 17
How to Make a Field read-only in Odoo 17
 
Ultra structure and life cycle of Plasmodium.pptx
Ultra structure and life cycle of Plasmodium.pptxUltra structure and life cycle of Plasmodium.pptx
Ultra structure and life cycle of Plasmodium.pptx
 
CapTechU Doctoral Presentation -March 2024 slides.pptx
CapTechU Doctoral Presentation -March 2024 slides.pptxCapTechU Doctoral Presentation -March 2024 slides.pptx
CapTechU Doctoral Presentation -March 2024 slides.pptx
 
Philosophy of Education and Educational Philosophy
Philosophy of Education  and Educational PhilosophyPhilosophy of Education  and Educational Philosophy
Philosophy of Education and Educational Philosophy
 
How to Add a many2many Relational Field in Odoo 17
How to Add a many2many Relational Field in Odoo 17How to Add a many2many Relational Field in Odoo 17
How to Add a many2many Relational Field in Odoo 17
 
Easter in the USA presentation by Chloe.
Easter in the USA presentation by Chloe.Easter in the USA presentation by Chloe.
Easter in the USA presentation by Chloe.
 
Clinical Pharmacy Introduction to Clinical Pharmacy, Concept of clinical pptx
Clinical Pharmacy  Introduction to Clinical Pharmacy, Concept of clinical pptxClinical Pharmacy  Introduction to Clinical Pharmacy, Concept of clinical pptx
Clinical Pharmacy Introduction to Clinical Pharmacy, Concept of clinical pptx
 

Schedule y

  • 1. BY DR KUMAR GOURAV PG resident, pharmacology 1
  • 2.  Definition  Introduction  Regulatory framework of India  Rules in schedule Y  Good clinical practice rules  Informed consent  Amendments  Organisation  Institutional ethical committee  Compensation rules  SAE reporting 2
  • 3.  Schedule Y refers to the requirements and guidelines for permission: 1. To import 2. Manufacture of new drugs for sale or 3. To undertake clinical trials in India. 3
  • 4.  At present the following acts and rules regulate the manufacture, export and clinical research of drugs and cosmetics in India : 1. Drugs and Cosmetics Act, 1940 2. Drugs and Cosmetics rules, 1945 3. Pharmacy Act, 1948 4. Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 4
  • 5. 5. Narcotic Drugs and Psychotropic Substances Act,1985 6. Medicinal and Toilet preparation (Excise Duties) Act, 1955 7. Drugs (Price Control ) Order, 1955 under Essential Commodities Act, 1955 5
  • 6.  The Main regulatory laws operating in India are the Drug and Cosmetics Act (1940) and the Drugs and Cosmetics Rules (1945).  The Act and Rules are binding on allopathic and other systems of medicine and regulate imports, manufacture, distribution, and sale of drugs in India 6
  • 7.  The enforcement came into existence in 1988 .  Revised version of Schedule Y in line with ICH- GCP (International Council of Harmonization and Good Clinical Practice) standard was put forth in 1995. 7
  • 8.  Rules 122 A, 122 B, 122 D, 122 DA, 122 DAA, 122 DAB, 122 E, 122 DD of the Drugs and Cosmetics Rules (1945) deals with schedule Y 8
  • 9. RULES PERMISSION FOR 122 A To import New drugs 122 B To manufacture New drugs 122 D To Import or Manufacture fixed dose combinations 122 DA To conduct clinical trials for New Drug/Investigational New drug 122 DAA Definition of Clinical Trial 122 DAB Reports of Serious Adverse Events (SAEs) including deaths. 122 E New Drug 122 DD Registration of Ethics Committee (EC). 9
  • 10.  A systematic study of new drug(s) in human subject(s) to generate data for discovering and/or verifying the clinical, pharmacological (including pharmaco –dynamic and pharmaco -kinetic) and/or adverse effects with the objective of determining safety and/ or efficacy of the new drug. 10
  • 11.  A drug which has not been used in the country , new claim for a drug already approved, FDC (combined for the first time or change in ratio) and all vaccines. 11
  • 12.  Some highlights of Schedule Y in terms of its appendices; which provide the guidelines to conduct clinical trials are:  Appendix V – Informed consent Appendix VII – Undertaking by the Investigator Appendix VIII – Ethics Committee Appendix X – Contents of Protocol Appendix XI – Data elements for reporting SAE 12
  • 13.  It shall made in Form 44 accompanied with the following data in accordance with appendices, namely 1. Clinical and pharmaceutical information 2. Animal pharmacology data 3. Animal Toxicology data 4. Human Clinical pharmacology data 5. Regulatory status in other countries 6. Prescribing information 13
  • 14. 1. Approval for Clinical trials  Clinical trials on a New drug shall be initiated only after permission by licensing authority and approval from EC .  All trial Investigator(s) should possess appropriate qualifications,  Protocol amendments if become necessary before initiation or during the course of a clinical trial, all such amendments should be notified to the Licensing Authority in writing 14
  • 15. 2. Responsibilities of Sponsor  Implementing and maintaining quality assurance  Submit status report to the licensing authority periodically  Serious adverse event (SAE) should be reported to the licensing authority within 14 calendar days.  In case of studies prematurely discontinued for any reason including lack of commercial interest in pursuing the new drug application, a summary report should be submitted within 3 months. 15
  • 16. 3. Responsibilities of Investigator  The Investigator(s) shall be responsible for the conduct of the trial according to the protocol  Ensure adequate medical care is provided to the subject  SAE and unexpected AE should be reported to the sponsor within 24 hrs and to the EC within 7 working days 16
  • 17. 4.Informed consent  Freely given informed written consent  Provide information about the study verbally and in written  Non-Technically and understandable language.  Legally acceptable representative 17
  • 18. 5.Responsibilities of ethics committee  Approval trial protocol to safe guard right, safety and well being of all trial subject  Particular care to protect right, safety and well being of all vulnerable subjects 18
  • 19. 1. Geriatrics They should be included in Phase III clinical trials (and in Phase II trials, at the Sponsor's option) in meaningful numbers, if 1. The disease is characteristically a disease of aging 2. Substantial numbers of geriatric patients 25
  • 20. 3.Common in the elderly are likely to be encountered 4.When the new drug is likely to alter the geriatric patient's response 26
  • 21.  Begin with older children before extending the trial to younger children and then infants.  If the new drug is for diseases predominantly or exclusively affecting paediatric patients, clinical trial data should be generated in the paediatric population except for initial safety and tolerability data 27
  • 22.  Diseases occurring in both adults and pediatric patients, for which there are currently no or limited therapeutic options, pediatric population should be included in the clinical trials early, following assessment of initial safety data and reasonable evidence of potential benefit.  Written informed consent should be obtained from the parent/legal guardian. 28
  • 23.  They should be included in clinical trials only when the drug is intended for use by pregnant/nursing women or fetus / nursing infants  Where the data generated from women who are not pregnant or nursing, is not suitable. 29
  • 24.  follow-up data on the pregnancy, fetus and child will be required.  Where applicable, excretion of the drug or its metabolites into human milk should be examined 30
  • 25.  closely monitored new drugs clinical safety  Periodic Safety Update Reports (PSUR)- to report all relevant new information  PSUR shall be submitted every 6months for the first 2 years  New studies specifically planned or conducted to examine a safety issue should be described in the PSURs. 31
  • 26.  conducted according to the guidance for BA and BE studies  Evaluation of the effect of food on absorption following oral administration  All bioavailability and bioequivalence studies should be conducted according to the Guidelines for Bioavailability and Bioequivalence studies as prescribed. 32
  • 27.  Good Clinical Practices (GCP) is an international ethical & scientific quality standard for designing, conducting, recording & reporting trials that involve the participation of human subjects.  It ensures the : RIGHTS SAFETY WELL BEING 33
  • 28.  The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) is a joint initiative of the experts in pharmaceutical industry of Europe, Japan and the United States to discuss scientific and technical aspects of pharmaceutical product registration. 34
  • 29.  Released in Dec 2001(Developed by CDCSO and endorsed by DCGI)  In general, in line with ICH GCP  Has Revised Schedule Y (Jan 2005) 35
  • 30.  2.1 Clinical trials should be conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki, and that are consistent with GCP and the applicable regulatory requirement(s). 36
  • 31.  2.2 Before a trial is initiated, risks and inconveniences should be weighed against the anticipated benefit for the individual , trial subject and society. A trial should be initiated and continued only if the anticipated benefits justify the risks. 37
  • 32.  2.3 The rights, safety, and well-being of the trial subjects are the most important considerations and should prevail over interests of science and society.  2.4 The available nonclinical and clinical information on an investigational product should be adequate to support the proposed clinical trial. 38
  • 33.  2.5 Clinical trials should be scientifically sound, and described in a clear, detailed protocol.  2.6 A trial should be conducted in compliance with the protocol that has received prior institutional review board (IRB)/independent ethics committee (IEC) approval/favorable opinion. 39
  • 34.  2.7 The medical care given to, and medical decisions made on behalf of, subjects should always be the responsibility of a qualified physician or, when appropriate, of a qualified dentist.  2.8 Each individual involved in conducting a trial should be qualified by education, training, and experience to perform his or her respective task(s). 40
  • 35.  2.9 Freely given informed consent should be obtained from every subject prior to clinical trial participation.  2.10 All clinical trial information should be recorded, handled, and stored in a way that allows its accurate reporting, interpretation and verification. 41
  • 36.  2.11 The confidentiality of records that could identify subjects should be protected, respecting the privacy.  2.12 Investigational products should be manufactured, handled, and stored in accordance with applicable good manufacturing practice (GMP).  2.13 Systems with procedures that assure the quality of every aspect of the trial should be implemented. 42
  • 37. 1. Participation 2. Title 3. Research team 4. Research funding 5. Study location 6. A brief introduction about the study 7. Need for the study 43
  • 38. 8. No of participants 9. Reason for inclusion of that participant. 10. Duration of participation 11. Methodology in detail 12. Responsibility of the participant. 13. Benefit of the study 14. Risk of the study 44
  • 39. 15. Protection from harm 16. Privacy 17. Protection of privacy 18. Confidentiality 19. Compensation 20. Use of data 21. Voluntariness, no force 45
  • 40. 22. Right to refuse, right to withdraw, patient care right not affected 23. Time to decide 24. Clarify doubts: contact information 25. Retain a copy 46
  • 41.  Same thing should be written by the participant with : Name Date Address Phone no 47
  • 42. 48
  • 43.  Rule 122DAB –Compensation in case of injury or death during clinical trial(CT).  Rule 122DAC- Permission to conduct Clinical Trial subject to certain Conditions, Authority for CT inspections, Actions in case of non-compliance  Rule 122DD -Registration of Ethics Committee - Requirements and guidelines for registration of Ethics Committee 49
  • 44.  Informed Consent 1. A-V recording of informed consent process is required for vulnerable subjects in NCE/ NME trials. 2. For anti-HIV & anti-leprosy drug trials, only audio recording. 3. Essential elements in ICF –Possibility of failure of investigational product . –Placebo will not any therapeutic effect . 50
  • 45.  The CT in relation to a new drug or investigational new drug in humans has to generate data for discovering or verifying its pharmacological interactions including pharmacodynamics, pharmacokinetic and adverse effects in order to determine the safety, efficacy or tolerance of new drugs. 51
  • 46.  The New Drug Regulatory Process come under the purview of the Drugs Controller General of India (DCGI), who is the head of the Central Drugs Standard Control Organization (CDSCO), located in New Delhi. 52
  • 47. 53
  • 48.  The DCGI is supported by various bodies, such as the Indian Council of Medical Research (ICMR) and Department of Biotechnology (DBT) in the evaluation of specific therapies or clinical trials.  The ICMR, for example, provides expert advice in evaluation of Phase I trials or clinical trials relevant to national priorities, eg, malaria, AIDS etc. 54
  • 49. Consist of 8-12 members: 1. Chairperson 2. 1-2 from basic medical science area 3. 1-2 clinicians 4. 1 legal expert 5. 1 representative of NGO 6. 1 philosopher 7. 1 lay person from the society 8. Member secretary 55
  • 50.  To provide competent review of all ethical aspects of the project  Undertake review free from bias and influence  Provide advice to the researchers on all aspects of welfare and safety of research participants  To protect dignity, rights and well-being of the potential research participants. 56
  • 51.  To ensure universal ethical values and international scientific standards in terms of local community values and customs.  To assist in the development and the education of research community responsive to local health care requirements 57
  • 52. 58
  • 53.  Rule of compensation applies to only those adverse events (AEs) that are required to be reported.  As per the rules, all serious AEs (SAEs) are to be reported within a stipulated time frame.  AE that do not fall into the SAE category are not required to be expeditiously reported and, therefore, do not fall under the clause of compensation. 59
  • 54.  The final formula for calculating compensation is: (8,00,000 x age factor x risk factor) 99.37 -where 800,000 rupees is the base amount; -age factor varies from 228.54 (≤ 16 years) to 99.37 (≥ 65 years); -the risk factor (ranging from 0.5 to 4.0) is decided on the basis of trial participants 60
  • 55. (i) SAE causing permanent disability to the subject. Compensation = (D x 80 x C) 100 x 100 where, D = percentage disability the subject has suffered, C = quantum of compensation which would have been due for payment to the subject’s nominee(s) in case of death of the subject 61
  • 56. (ii) SAE causing congenital anomaly or birth defect. The following four situations may arise due to congenital anomaly or birth defect: (a) Still birth. (b) Early death due to anomaly. (c) No death but deformity which can be fully corrected through appropriate intervention. (d) Permanent disability (mental or physical) 62
  • 57.  For all the above-mentioned situations, compensation of a fixed amount of 400,000 rupees is applicable.  However, for situations (c) and (d), medical management, as long as required, has to be provided by the sponsor, in addition to the above- mentioned fixed amount of 400,000 rupees. 63
  • 58. (iii) SAE causing life-threatening disease. Compensation = N x W where N = number of days for which the trial subject remained in a life-threatening situation requiring medical care, irrespective of number of days of hospitalization; W = minimum wage per day of an unskilled worker. 64
  • 59. (iv) Reversible SAE in case it is resolved. In this situation, the compensation amount will be double the amount applicable for situation (iii), explained above. 65
  • 60. 66
  • 61.  An event is serious when the patient outcome is: 1. death 2. Is life-threatening 3. Requires inpatient hospitalization or prolongation of existing hospitalization 4. Results in persistent or significant Disability/incapacity 5. Is a congenital anomaly/birth defect 6. Require intervention to prevent permanent damage 67
  • 62. A. As per the regulations (Schedule Y of Drugs & Cosmetics Rules), all Unexpected SAEs have to be reported to CDSCO within 14 calendar days. B. Every report (both initial as well as follow-up reports) should be submitted along with a covering letter. A template of covering letter is available in Annexure II. 68
  • 63. C. Covering letter should be prepared using the template as guide, and printed on the company’s/ CRO’s letter head. D. Instructions are provided in the template as highlighted text in “Italics”. Please delete all instructions from your final letter. 69
  • 64. E. All the sections of the covering letter should be completed. G. Capture whether it is “initial” or “follow-up” report. 70
  • 65. 71
  • 66.  http://www.cdsco.nic.in/writereaddata/CDSCO- GuidanceForIndustry.pdf  Drugs and Cosmetics act and rules 1945 available at http://www.cdsco.nic.in/writereaddata/Drugs&CosmeticAct. pdf  Gupta YK, Pradhan AK, Goyal A, Mohan P. Compensation for clinical trial-related injury and death in India: Challenges and the way forward. Drug Saf. 2014;37:995–1002. 72
  • 67. 73

Editor's Notes

  1. A New Molecular Entity or NME is a drug that has an active moiety that has not been previously approved by the FDA. However, an NME differs from an NCE or New Chemical Entity which has no active moiety that has ever been FDA-approved before.
  2. large, diverse and treatment-naive patient population, trained human resources, good clinical practice compliant investigators/sites, relatively low cost of conducting clinical trials as compared with the developed world) to the fullest during the period between 2005 and 2012, a total of 2,868 clinical trial participants died, of which 89 deaths were considered to be related to trials [6]. Out of these, compensation was paid to the relatives of the deceased in 86 cases; while in three cases, the whereabouts of relatives could not be traced for payment of the compensation